Unit of PharmacoEpidemiology & PharmacoEconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands.
Hum Reprod. 2009 Nov;24(11):2796-800. doi: 10.1093/humrep/dep260. Epub 2009 Jul 22.
Authorities concerned by rising healthcare costs have a tendency to target reproductive treatments because of the perception that infertility is a low priority. In 2004 German health authorities introduced a 50% co-payment for patients, in an effort to save cost. We explored the impact of this pricing policy on the utilization of reproductive treatments in Germany.
Using aggregated annual in-vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) cycle data in Germany, we evaluated the relationship between changes in the number of cycles in relation to changes in costs faced by consumers following the introduction of a patient co-payment from 'no fees' to 1500-2000 euros by estimating the short-run price-elasticity of demand. The impact of introducing patient co-payments for IVF/ICSI on the likelihood of switching to other low-cost fertility treatments was evaluated using the cross-price elasticity methodology. RESULTS The reduction in demand for IVF and ICSI cycles in the year following the introduction of patient co-payments resulted in elasticities of -0.41 and -0.34, respectively. The price-elasticity for the combined reduction of IVF/ICSI in relation to the co-payment was estimated to be -0.36. The cross-price elasticity for clomifene was close to zero (-0.01) suggesting that demand for these interventions are independent of each other and no substitution occurred.
We report price elasticities for IVF and ICSI of -0.41 and -0.34 after introducing a 500-2000 euros co-payment. These findings likely represent short-run elasticities that are likely to vary over time as factors that influence the supply and demand for fertility treatments change.
由于认为不孕不育不是优先事项,有关当局往往倾向于针对生殖治疗来控制医疗成本的增长。2004 年,德国卫生当局对患者实行了 50%的共付额,以节省成本。我们探讨了这项定价政策对德国生殖治疗利用的影响。
使用德国汇总的年度体外受精(IVF)和胞浆内精子注射(ICSI)周期数据,我们通过估计引入患者共付额后(从“无费用”到 1500-2000 欧元)消费者面临的成本变化与周期数量变化之间的关系,评估了需求的短期价格弹性。使用交叉价格弹性方法评估了引入 IVF/ICSI 患者共付额对转向其他低成本生育治疗的可能性的影响。
引入患者共付额后,IVF 和 ICSI 周期的需求减少,分别导致需求弹性为-0.41 和-0.34。共付额与 IVF/ICSI 联合减少的价格弹性估计为-0.36。氯米芬的交叉价格弹性接近零(-0.01),表明这些干预措施的需求彼此独立,没有发生替代。
我们报告了引入 500-2000 欧元共付额后 IVF 和 ICSI 的价格弹性分别为-0.41 和-0.34。这些发现可能代表短期内的弹性,随着影响生育治疗供需的因素发生变化,这些弹性可能会随时间而变化。